Useful Resources for BHRT

 

Progesterone receptor modulates ERα action in breast cancer

Progesterone receptor modulates ERα action in breast cancer Nature volume 523, pages 313–317 (16 July 2015)

Roles for estrogen and progesterone in breast cancer prevention

Jerry DJ: Roles for estrogen and progesterone in breast cancer prevention. Breast Cancer

Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer

Fournier et al J Clin Oncol 26 (8):1260-1268, 2008.

Inadequate corpus luteal function in women with benign breast diseases

Sitruk-Ware et al J Clin Endocrinol Metab 44, 771, 1977.

Endogenous sex hormones and subsequent breast cancer in premenopausal women

Micheli et al Int J Cancer 112, 312-318, 2004.

Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease

Plu-Bureau G et al Cancer Detect Preve 23(4), 290-296, 1999.

Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey

Fitzpatrick LA, Pace C, Witta B. Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med. 2000;9(4):381–387.

Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women

Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause. 2002;9:253–263.

Menopausal hormone replacement therapy with continuous daily oral mircronized progesterone

Hargrove JT, Maxon WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral mircronized progesterone. Obstet Gynecol. 1989;73(4):606–612.

Effects of progestogens on the postmenopausal breast

de Lignières B. Effects of progestogens on the postmenopausal breast. Climacteric. 2002;5(3):229–235.

Progestins and progesterone in hormone replacement therapy and the risk of breast cancer

Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005;96(2):95–108.

Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines

Ory K, Lebeau J, Levalois C, et al. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res Treat. 2001;68(3).

Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast

Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84(12):4559–4565.

Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation

Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 1992;52(23):6539–6546.

Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys

Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat. 2007;101(2):125–134.

Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions

van der Burg B, Kalkhoven E, Isbrücker L, de Laat SW. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992;42(5):457–465.

Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo

Chang KJ, Lee TY, Linares-Cruz G, Fournier S, de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril. 1995;63(4):785–791.

The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue

Barrat J, de Lignieres B, Marpeau L, et al. Effect in vivo de l’adminstration locale de progesterone sur l’activite mitotique des glaactorphores humains. [The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.] J Gynecol Obstet Biol Reprod (Paris). 1990;19(3):269–274.

Antiestrogen action of progesterone in breast tissue

Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat. 1986;8(3):179– 188.

Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53

Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998;28(6):360–369.

Progesterone inhibits glucocorticoid dependent aromatase induction in human adipose fibroblasts

Schmidt M, Renner C, Löffler G. Progesterone inhibits glucocorticoid dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998;158(3):401–407.

The estrogenic activity of synthetic progestins used in oral contraceptives

Jordan VC, Jeng MH, Catherino WH, Parker CJ. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer. 1993;71(4 suppl):1501–1505.

Pregnancy, progesterone and progestins in relation to breast cancer risk

Campagnoli C, Abba C, Ambroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2005;97(5):441–450.

Effect of norethisterone acetate on estrogen metabolism in postmenopausal women

Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res. 2000;32(10):436–439.

Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis

Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72(2):163–172.

Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort

Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–454.

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.

Serum hormone levels in pre- menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies

Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in pre- menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control. 1990;1(1):51–58.

Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States)

Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States). Cancer Causes Control. 2002;13(9):847–854.

An overview of menopausal oestrogenprogestin hormone therapy and breast cancer risk

Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogenprogestin hormone therapy and breast cancer risk. Br J Cancer. 2005;92(11):2049–2058.

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328–332.

Breast cancer incidence in women with a history of progesterone deficiency

Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol. 1981;114(2):209–217.

Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer

Badwe RA, Wang DY, Gregory WM, et al. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer. 1994;30A(4):445–448.

First pregnancy characteristics and subsequent breast cancer risk among young women

Innes KE, Byers TE. First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer. 2004;112(2):306–311.

Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cycle arrest

Paruthiyil S, Parma H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cycle arrest. Cancer Res. 2004;64(1):423–428.

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sties

Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sties. Science. 1997;277(5331):1508–1510.

Mechanisms of estrogen action

Nilsson S, Mäkelä S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev.2001;81(4):1535–1565.

Estrogen receptor beta acts a dominant regulator of estrogen signaling

Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts a dominant regulator of estrogen signaling. Oncogene. 2000;19(43):4970– 4978.

Quantitative structure activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding

Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006;147(9):4132–4150.

Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma

Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (Copenh). 1980;233:17–27.

Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen

Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF, Abbo KM. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer. 1989;63(9):1685–1692.

Estriol prevention of mammary carcinoma induced by 7,12- dimethylbenzanthracene and procarbazine

Lemon HM. Estriol prevention of mammary carcinoma induced by 7,12- dimethylbenzanthracene and procarbazine. Cancer Res. 1975;35(5):1341– 1353.

Oestrogen profiles of Asian and North American women

MacMahon B, Cole P, Brown JB, et al. Oestrogen profiles of Asian and North American women. Lancet. 1971;2(7730):900–902.

Differential response of estrogen receptor alpha and receptor beta to partial estrogen agonists/antagonists

Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998;54(1):105–112.

The major metabolite of equilin, 4- hyroxyequilin, autoxidizes to an oquinone with isomerizes to the potent cytotoxin 4-hydroyequilenin-o-quinone

Zhang F, Chen Y, Pisha E, et al. The major metabolite of equilin, 4- hyroxyequilin, autoxidizes to an oquinone with isomerizes to the potent cytotoxin 4-hydroyequilenin-o-quinone. Chem Res Toxicol. 1999;12(2):204–213.

A metabolite of equine estrogens, 4- hydroxyequilenin, induces DNA damage and apop tosis in breast cancer cell lines

Chen Y, Liu X, Pisha E, et al. A metabolite of equine estrogens, 4- hydroxyequilenin, induces DNA damage and apop tosis in breast cancer cell lines. Chem Res Toxicol. 2000;13(5):342–350.

Equineestrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases

Zhang F, Swanson SM, van Breemen RB, et al. Equineestrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol. 2001;14(12):1654–1659.

Oestrogen fractions during early reproductive life in the aetiology of breast cancer

Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969;1(7595):604–606.

Molecular and kinetic basis for the mixed

Melamed M, Castaño E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed

Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol

agonist/antagonist activity of estriol. Mol Endocrinol. 1997;11(12):1868–1878.

Differentiation of the mammary gland and susceptibility to carcinogenesis

Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat. 1982;2(1):5–73.

Pregnancy related protection against breast cancer depends on length of gestation

Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R. Pregnancy related protection against breast cancer depends on length of gestation. Br J Cancer. 2002;87(3):289–290.

Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women?

Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res. 2001;61(8):3326–3329.

Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians

Lemon HM. Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians. J Surg Oncol. 1972;4(3):255–273.

Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture

Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977;37(6):1901–1907.

Reduced estriol excretion in patients with breast cancer prior to endocrine therapy

Lemon HM, Wotiz HH, Parsons L, Mozden PJ. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA. 1966;196(13):1128–136.

Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys

Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 1998;83(2):649–659.

Medroxyprogesterone Acetate and Dihydrotestosterone Induce Coronary Hyperreactivity in Intact Male Rhesus Monkeys

Mishra RG, Hermsmeyer RK, Miyagawas K, et al. Medroxyprogesterone acetate and

Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

Miyagawa K, Roöch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3(3):324–327.

Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis

Adams MR, Register TC, Golden DL, Wagner JD, Williams J. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(1):217–221.

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199–208.

L-norgestrel and progesterone have different influences on plasma lipoproteins

Fåhraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest. 1983;13(6):447–453.

Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins

Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl. 1984;127:1–37.

Effects of different progestogens on lipoproteins during

Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during

Estrogen plus progestin and risk of venous thrombosis

Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 20, 2004;292(13):1573–1580.

Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study

Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.

Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women

Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7):2154–2159.

Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol

Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol. 1991;77(2):235–240.

Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells

Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21(2):243–248.

Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy

Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism.1993;42(7):846–853.

Thrombotic stroke in an otherwise healthy middle aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate

Feeman WE Jr. Thrombotic stroke in an otherwise healthy middle aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. J Gend Specif Med. 2000;3(8):62–64.

Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia- reperfusion injury

Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia- reperfusion injury. Menopause. 2006;13(1):80–86.

Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women

Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156(1):66–71.

Low- dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters

Bolaji II, Grimes H, Mortimer G, Tallon DF, Fottrell PF, O’Dwyer EM. Low- dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol Reprod Biol. 1993;48(1):61–68.

Estrogen and progesterone inhibit vascular smooth muscle proliferation

Morey AK, Pedram A, Razandi M, et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138(8):3330– 3339.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women

Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17(11):3071–3078.

Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women

Martinez C, Basurto L, Zarate A, Saucedo R, Gaminio E, Collazo J. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas. 2005;50(1):39–43.

Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users

Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 pt 1):339–346.

Natural progesterone and antihypertensive action

Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. Bri Med J. 1985(6461);290:13–14.

Estriol in the management of the menopause

Tzingounis VA, Aksu MF, Greenblatt RB. Estriol in the management of the menopause. JAMA.

Efficacy and safety of estriol replacement therapy for climacteric women

Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Chin Med J (Taipei). 1995;55:386–391.

Treatment of climacteric complaints with oestriol

Perovi D, Kopajtic B, Stankovi T. Treatment of climacteric complaints with oestriol. Arzneimittel-Forschung. 1975;25(6):962–964.

The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms

van der Linden MC, Gerretsen G, Brandhorst MS, Ooms EC, Kremer CM, Doesburg WH. The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. Eur J Obstet Gynecol Reprod Biol. 1993;51(1):29–33.

Oestriol in the treatment of postmenopausal urgency: a multicentre study

Cardoza L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18(1):47–53.

Progesterone and bone: actions promoting bone health in women

Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010 Oct 31;2010:845180.

Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study

Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC; Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002 Nov 6;288(17):2123-9.

Estrogen replacement therapy and risk of Alzheimer disease

Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996 Oct 28;156(19):2213-7.

Comparative measurements of serum Estriol, Estradiol, and Estrone in non-pregnant, premenopausal women: A preliminary investigation

Wright JV, Schliesman B, Robinson L. Comparative measurements of serum Estriol, Estradiol, and Estrone in non-pregnant, premenopausal women: A preliminary investigation. Altern Med Rev 1999;4(4):266-270.

The bioidentical hormone debate: are bioidentical hormones (Estradiol, Estriol, and Progesterone) safer or more efficacious than commonly used synthetic versions in Hormone Replacement Therapy?

Holtorf K. The bioidentical hormone debate: are bioidentical hormones (Estradiol, Estriol, and Progesterone) safer or more efficacious than commonly used synthetic versions in Hormone Replacement Therapy? Postgrad Med 2009;121(1): 73-85.

Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11

Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24(44):6605–6616.

Loss of Erbeta expression as a common step in estrogen-dependent tumor progression

Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of Erbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11(3):537–551.

Increased risk of endometrial carcinoma among users of conjugated estrogens

Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4;293(23):1167-70.